Financial Performance - For the year ended December 31, 2025, the company reported an operating loss of $40.2 million, compared to a loss of $16.8 million for 2024, representing an increase of $23.3 million[569]. - The total operating expenses for 2025 were $40.2 million, up from $16.8 million in 2024, indicating a significant rise in operational costs[584]. - The company had an accumulated deficit of $130.4 million as of December 31, 2025[569]. - The company continues to incur significant operating losses and will require substantial additional funding to support ongoing operations and growth strategies[574]. - The company incurred an operating loss of $40.2 million for the year ended December 31, 2025, with an accumulated deficit of $130.4 million[600]. - Other income decreased by $19.2 million for the year ended December 31, 2025, primarily due to a decrease in gains from financial instruments[589]. Cash Flow and Financing - Cash used in operating activities was $28.1 million for the year ended December 31, 2025, consisting of a net loss of $39.7 million offset by $0.9 million in non-cash charges[604]. - The company had negative cash flows from operations of $28.1 million for the year ended December 31, 2025[600]. - Cash provided by financing activities was $20.9 million for the year ended December 31, 2025, including proceeds from discounted exercises and private placements[607]. - The company completed a private placement in January 2026 for gross proceeds of $75.5 million, selling 6,815,296 Common Shares and warrants[597]. - In January 2026, the company raised gross proceeds of $75.5 million from the sale of Common Shares and warrants in a private placement[571]. - The company expects existing cash to be sufficient to fund operating expenses through 2027 following the January 2026 Private Placement[601]. - The company will seek additional funding through public and private financings, debt financings, and collaboration agreements to support future clinical activities[602]. Expenses and Investments - Research and development expenses increased by $22.7 million, or 214%, for the year ended December 31, 2025, primarily due to increased spending on the lead program PMN310[585]. - General and administrative expenses increased by $0.6 million, or 10%, for the year ended December 31, 2025, primarily due to increased employee salaries and benefits[588]. Risk Management - The company is exposed to credit risk primarily through cash and short-term investments, managing this risk by placing cash with accredited financial institutions[615]. - Liquidity risk is managed by continuously monitoring actual and projected cash flows, with the Board reviewing the operating budget[616]. - The company does not believe foreign exchange risk had a material effect on its financial condition or results of operations for the years ended December 31, 2025, or 2024[617]. - Inflation has not materially affected the company's business, financial condition, or results of operations during the years ended December 31, 2025, or 2024[618]. - As of December 31, 2025, a hypothetical 10% change in interest rates would not materially impact the company's financial statements[615]. Revenue Generation - The company has not generated any revenue since inception and does not expect to do so in the near future[576]. - The company sold 40,795 Common Shares for net proceeds of $0.7 million during the year ended December 31, 2025[593]. - The company sold 3,034 shares for net proceeds of approximately $0.2 million during the year ended December 31, 2024[591].

Financial Performance - ProMIS Neurosciences reported a net loss of $39.7 million for the year ended December 31, 2025, with cash reserves of $6.1 million[14]. - The company reported a net loss of $39,719,147 for 2025, compared to a net income of $2,778,873 in 2024, indicating a substantial decline in profitability[29]. - The total current assets decreased to $9,182,421 in 2025 from $18,911,456 in 2024, representing a decline of 51.5%[27]. - Total liabilities increased to $10,441,013 in 2025, up from $2,423,280 in 2024, marking an increase of 331.5%[27]. - The accumulated deficit grew to $130,406,220 in 2025, compared to $90,687,073 in 2024, reflecting an increase of 43.8%[27]. - The total shareholders' equity shifted from $16,488,176 in 2024 to a deficit of $1,258,592 in 2025, indicating a negative change in equity position[27]. - The change in fair value of financial instruments resulted in a gain of $5,592 in 2025, contrasting with a significant gain of $22,581,477 in 2024[29]. - The company reported no interest expense in 2025, compared to an expense of $76,775 in 2024, reflecting a reduction in financial costs[29]. Research and Development - The PRECISE-AD Phase 1b trial was fully enrolled with 144 patients, exceeding the target of 128, and is expected to complete six-month assessments in Q2 2026[3][9]. - PMN310 has demonstrated a favorable safety profile with no treatment-related serious adverse events reported to date[4]. - Research and development expenses for 2025 were $33.4 million, significantly higher than $10.6 million in 2024, reflecting costs for the PRECISE-AD trial[17]. - The company anticipates presenting unblinded top-line data from the PRECISE-AD trial in early 2027[5][10]. - PMN310 received Fast Track Designation from the FDA in July 2025, which may facilitate development efforts[7][19]. - The development of a subcutaneous formulation of PMN310 has been accelerated to improve patient experience[7][16]. - The company is exploring the potential of PMN310 in earlier patient populations with preclinical and asymptomatic Alzheimer's disease[8]. Operating Expenses - Total operating expenses for 2025 reached $40,167,308, a significant increase of 138.5% compared to $16,827,478 in 2024[29]. - Research and development expenses surged to $33,379,321 in 2025, up from $10,637,976 in 2024, reflecting a growth of 213.5%[29]. - General and administrative expenses increased to $6.8 million in 2025 from $6.2 million in 2024, primarily due to a rise in employee headcount[17]. Shareholder Information - The weighted-average outstanding common shares, basic, rose to 1,756,844 in 2025 from 1,036,799 in 2024, an increase of 69.5%[29].

Core Insights - ProMIS Neurosciences has completed enrollment for its PRECISE-AD Phase 1b trial, with 144 patients enrolled, exceeding the target of 128, indicating strong interest in PMN310's therapeutic potential [3][8] - The company reported a net loss of $39.7 million for the year ended December 31, 2025, with cash reserves of $6.1 million, reflecting its investment in advancing the PRECISE-AD trial [12][24] - PMN310 has shown a favorable safety profile with no treatment-related serious adverse events reported to date, and it is designed to minimize treatment-related side effects, particularly Amyloid-Related Imaging Abnormalities (ARIA) [4][15] Clinical Development - The PRECISE-AD trial is expected to complete six-month assessments in Q2 2026, with a blinded interim analysis anticipated in early Q3 2026 and top-line data expected in early 2027 [1][9] - PMN310 has been granted Fast Track Designation by the FDA, which may facilitate its development and regulatory engagement [7][15] - The company is also developing a subcutaneous formulation of PMN310 to improve patient experience and strengthen its competitive profile [6][13] Financial Overview - The company closed a financing round in early 2026, raising up to $175 million, which includes $75 million upfront and $100 million tied to future warrant exercises, providing a cash runway through 2027 [6][12] - Research and development expenses for 2025 were $33.4 million, significantly higher than the $10.6 million in 2024, primarily due to costs associated with the PRECISE-AD trial [12][24] - General and administrative expenses increased to $6.8 million in 2025 from $6.2 million in 2024, driven by a moderate increase in employee headcount [12][24] Pipeline and Future Directions - PMN267 and PMN442 are other key pipeline candidates targeting amyotrophic lateral sclerosis (ALS) and Parkinson's disease (PD), respectively, with PMN267 showing selectivity for pathogenic TDP-43 and PMN442 targeting alpha-synuclein [13][14] - The company is monitoring developments in preclinical and asymptomatic Alzheimer's disease trials, considering potential expansion into these areas based on PMN310's safety profile [8]

Core Viewpoint - ProMIS Neurosciences, Inc. is advancing its research on therapies for Alzheimer's disease and other neurodegenerative disorders, presenting findings at the Alzheimer's & Parkinson's Diseases Conference 2026 [1][2]. Company Overview - ProMIS Neurosciences is a clinical-stage biotechnology company focused on developing therapeutic antibodies and vaccines targeting toxic oligomers associated with neurodegenerative diseases [4]. - The company utilizes its proprietary EpiSelect™ platform to identify Disease Specific Epitopes (DSEs) on misfolded proteins, which are implicated in diseases like Alzheimer's, ALS, and Parkinson's [4][8]. Research and Development - The company will present two scientific posters at the AD/PD™ 2026 conference, showcasing its proprietary discovery platform and its approach to targeting toxic misfolded proteins [1][2]. - The lead product candidate, PMN310, is a humanized monoclonal antibody designed to selectively target toxic oligomers while avoiding plaque, potentially reducing amyloid-related imaging abnormalities (ARIA) [5][6]. - PMN310 has received Fast Track designation from the U.S. FDA as of July 2025, indicating its potential in treating Alzheimer's disease [5]. Clinical Trials - ProMIS initiated the PRECISE-AD trial, a Phase 1b clinical study to evaluate the safety and pharmacokinetics of PMN310 in patients with Mild Cognitive Impairment and mild Alzheimer's disease [6][7]. - The trial will assess the effects of PMN310 on biomarkers associated with Alzheimer's pathology and clinical outcomes, with a focus on safety and the risk of ARIA [7]. Presentation Details - The first presentation will focus on a vaccine designed against TDP-43 proteinopathies, while the second will discuss vaccination strategies targeting toxic alpha-synuclein species [3].

Summary of ProMIS Neurosciences Conference Call Company Overview - **Company**: ProMIS Neurosciences (Ticker: PMN, Nasdaq) - **Focus**: Treatment of neurodegenerative diseases, primarily in the dementia space, including Alzheimer's, ALS, Parkinson's, and Lewy body dementia [2][3] Key Milestones - **Phase 1b Study**: Completed enrollment of 144 patients for PMN 310, a lead product for Alzheimer's disease, in December 2025 [3] - **Financing**: Successfully raised up to $175 million from a syndicate of investors, ensuring full funding through data readout [3][4] Upcoming Catalysts - **Data Release**: Interim analysis expected mid-2026, with final top-line results by the end of 2026 [4][23] - **Study Design**: Robust 12-month, placebo-controlled, randomized trial aimed at providing definitive answers regarding the efficacy of PMN 310 [4][21] EpiSelect Platform - **Proprietary Technology**: The EpiSelect platform allows for the design of highly selective antibodies targeting toxic oligomers of amyloid beta protein, differentiating ProMIS from competitors [8][10] - **Antibody Development**: PMN 310 is designed to selectively target toxic oligomers while avoiding binding to non-toxic forms, which is a significant advantage over other antibodies [12][16] Safety and Efficacy - **ARIA Management**: The company aims to achieve ARIA (Amyloid-related imaging abnormalities) rates similar to placebo (9%-14%), which would be a significant improvement over existing treatments [24][25] - **Safety Signals**: No treatment-related serious adverse events reported so far, with a lower than expected dropout rate, indicating strong patient enthusiasm [29][30] Biomarker Analysis - **Biomarkers**: A comprehensive panel of biomarkers will be used to assess treatment effects, including p-tau217, neurogranin, and NfL [32][33] - **Predictive Value**: p-tau217 has been identified as a strong predictor of clinical benefit, with expectations for a downward trend in biomarkers indicating drug efficacy [34][41] Future Pipeline and Partnerships - **Expansion Potential**: Successful proof of concept in Alzheimer's could lead to expedited entry into pivotal Phase 3 studies, bypassing Phase 2 trials [44] - **Interest from Pharma**: Ongoing discussions with pharmaceutical companies for potential partnerships, particularly for ALS and other neurodegenerative programs [44][45] Conclusion - **Transformational Year**: 2026 is positioned as a watershed year for ProMIS, with significant data expected that could transform treatment paradigms in Alzheimer's disease and other neurodegenerative conditions [46]

Core Viewpoint - ProMIS Neurosciences, Inc. is actively participating in the Guggenheim Emerging Outlook: Biotech Summit 2026, highlighting its focus on developing next-generation therapies for Alzheimer's disease and other neurodegenerative disorders [1] Company Overview - ProMIS Neurosciences is a clinical-stage biotechnology company dedicated to discovering and developing therapeutic antibodies and vaccines that target toxic oligomers associated with neurodegenerative diseases [3] - The company utilizes its proprietary EpiSelect™ target discovery engine to identify Disease Specific Epitopes (DSEs) on misfolded proteins linked to diseases such as Alzheimer's, ALS, FTD, MSA, and PD [3] Product Development - PMN310 is the lead product candidate designed as a humanized monoclonal antibody that selectively targets toxic oligomers while avoiding plaque, potentially reducing amyloid-related imaging abnormalities (ARIA) [4] - PMN310 received Fast Track designation from the U.S. FDA in July 2025, indicating its potential for expedited development [4] Clinical Trials - Following positive results from the Phase 1a trial, ProMIS initiated the PRECISE-AD Phase 1b clinical trial to evaluate the safety, tolerability, and pharmacokinetics of PMN310 in patients with Mild Cognitive Impairment and mild Alzheimer's disease [5] - The PRECISE-AD trial is designed as a randomized, double-blind, placebo-controlled study with multiple ascending doses (5, 10, 20 mg/kg) and aims to assess the effects of PMN310 on biomarkers and clinical outcomes associated with Alzheimer's disease [5] EpiSelect Drug Discovery Engine - The EpiSelect platform enables the identification of conformational epitopes on toxic misfolded proteins, facilitating the development of selective therapeutic antibodies and vaccines [6] - PMN310 has shown high selectivity for toxic amyloid-beta oligomers without significant reactivity with other forms, potentially minimizing risks associated with targeting vascular or parenchymal amyloid [6]

Core Insights - ProMIS Neurosciences Inc. has entered into a securities purchase agreement to raise approximately $175 million through the issuance of common shares and warrants, aimed at extending its cash runway into 2028 and supporting key clinical milestones in Alzheimer's disease research [1][4] Financing Details - The financing includes the sale of 6,815,296 common shares at $10.77 each, 100,000 pre-funded warrants at a similar price with a minimal exercise price, and 725,221 common shares sold at $12.13 to affiliates and insiders [2] - The common share warrants have an exercise price of $14.40, are immediately exercisable, and will expire within 60 days of a defined milestone event or on February 3, 2031 [2] - The anticipated upfront gross proceeds from the financing are approximately $75 million, with potential additional proceeds of up to $100 million if all warrants are exercised [4] Investor Participation - The private investment in public equity (PIPE) financing is co-led by Janus Henderson and Ally Bridge Group, with participation from various institutional investors including Deep Track Capital and Wellington Management [3] Clinical Development Plans - ProMIS aims to use the proceeds to complete its Phase 1b clinical study for Alzheimer's disease and to accelerate the development of a subcutaneous formulation of PMN310, with blinded top-line data expected in mid-2026 and 12-month data by the end of 2026 [4]

Core Insights - Several small-cap biotech and healthcare companies experienced notable gains in after-hours trading, driven by recent corporate updates and clinical milestones Company Updates - Inspira Technologies Oxy B.H.N. Ltd. (IINN) rose 5.88% to $1.08 following a recent definitive agreement for a registered direct offering of its ordinary shares and a Standby Equity Purchase Agreement with YA II PN, Ltd. [2] - Galectin Therapeutics Inc. (GALT) increased by 1.79% to close at $6.27, despite no new corporate developments reported [3] - MediciNova, Inc. (MNOV) advanced 4.83% to $1.52 after successfully completing patient enrollment in its Phase 2 OXTOX study, evaluating MN-166 for chemotherapy-induced peripheral neuropathy in metastatic colorectal cancer patients [4] - Marker Therapeutics, Inc. (MRKR) gained 5.56% to $1.33 without any new company-specific announcements [5] - Sharps Technology, Inc. (STSS) climbed nearly 4% to $2.09, also without fresh updates [6] - DiaMedica Therapeutics Inc. (DMAC) rose 2.89% to $8.55 after a productive pre-IND meeting with the FDA regarding its planned study of DM199 in preeclampsia [6] - Corbus Pharmaceuticals Holdings, Inc. (CRBP) edged higher by 1.36% to $8.21, following the completion of its Phase 1a study of CRB-913 and initiation of the Phase 1b CANYON-1 trial [7] - ProMIS Neurosciences, Inc. (PMN) added 0.83% to $8.49, recovering slightly after a decline earlier in the day, with the completion of enrollment of 144 patients in its PRECISE-AD Phase 1b clinical trial for Alzheimer's disease [8]

Core Insights - ProMIS Neurosciences Inc. has completed enrollment of 144 patients in its PRECISE-AD Phase 1b clinical trial for PMN310, targeting early Alzheimer's disease [1][4] - The trial is designed to provide clinically and biologically meaningful insights, with interim data expected in Q2 2026 and final results in Q4 2026 [1][3] Company Overview - ProMIS Neurosciences is a clinical-stage biotechnology company focused on developing antibody therapeutics and vaccines for neurodegenerative diseases, including Alzheimer's disease, ALS, and Parkinson's disease [1][5] - The company utilizes its proprietary EpiSelect™ technology to identify Disease Specific Epitopes (DSEs) on misfolded proteins [5] Clinical Trial Details - The PRECISE-AD trial is a randomized, double-blind, placebo-controlled study assessing the safety, tolerability, pharmacokinetics, and clinical effects of PMN310, which selectively targets toxic soluble amyloid-beta oligomers [2][8] - PMN310 has shown a favorable safety profile with no treatment-related serious adverse events reported and minimal patient discontinuations [3][4] Future Expectations - The upcoming blinded 6-month interim analysis in Q2 2026 will evaluate key biomarkers, followed by a final unblinded top-line analysis expected in Q4 2026 [3][8] - The trial's design aims to provide sufficient power to detect effects on biomarkers and clinical outcomes, with a focus on reducing amyloid-related imaging abnormalities (ARIA) [8]

Core Insights - ProMIS Neurosciences Inc. is advancing its lead product candidate PMN310, a humanized monoclonal antibody designed to selectively target toxic oligomers associated with Alzheimer's disease (AD), potentially improving clinical outcomes and quality of life for patients and caregivers [3][10] - The ongoing PRECISE-AD trial is expected to complete enrollment by the end of 2025, with interim results anticipated in Q2 2026 and top-line results in Q4 2026 [1][11] Group 1: Key Findings and Implications - The study published in Alzheimer's & Dementia highlights the importance of selectively targeting soluble toxic Aβ aggregates, showing a correlation between selectivity for these oligomers and clinical efficacy [2][4] - PMN310 demonstrated the highest resistance to monomer competition among tested antibodies, preserving oligomer binding, which may translate into clinical benefits for patients [6][13] Group 2: Safety and Efficacy - PMN310's lack of binding to plaque or vascular deposits suggests a potentially lower risk of amyloid-related imaging abnormalities (ARIA), a common side effect of current anti-amyloid therapies [5][10] - Preclinical studies indicated that high-dose chronic administration of PMN310 did not produce microhemorrhages in plaque-bearing mice, supporting the hypothesis of reduced ARIA risk [6][10] Group 3: Clinical Trial Design - The PRECISE-AD trial is designed to evaluate the safety, tolerability, and pharmacokinetics of PMN310 in patients with Mild Cognitive Impairment due to AD and mild AD, with a targeted enrollment of 128 patients [11] - This trial will be the first to examine the effects of a monoclonal antibody directed solely against toxic amyloid-beta oligomers on biomarkers associated with AD pathology and clinical outcomes [11][13]